JP Morgan Maintains Overweight on Apellis Pharmaceuticals, Lowers Price Target to $64
JP Morgan Maintains Overweight on Apellis Pharmaceuticals, Lowers Price Target to $64
JP摩根維持對Apellis Pharmaceuticals的增持,將價格目標下調至64美元。
JP Morgan analyst Anupam Rama maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Overweight and lowers the price target from $72 to $64.
JP摩根分析師Anupam Rama維持Apellis Pharmaceuticals (納斯達克:APLS)的增持評級,將目標價從72美元下調至64美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。